BioCryst 
Welcome,         Profile    Billing    Logout  
 10 Products   124 Diseases  10 Products   13 Trials   1200 News 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rapivab (peramivir) / BioCryst
ChiCTR-IPR-15006047: REDUNING, a kind of traditional Chinese medicine injections, in the treatment of human H7N9 bird flu: A single-center, randomized, open, controlled clinical trial

Recruiting
4
60
 
Peramivir injection+REDUNING injection ;Peramivir injection
First Affiliated Hospital, College of Medcine, Zhejiang University; First Affiliated Hospital, College of Medcine, Zhejiang University, Jiangsu Kanion Pharmaceutical Co., Ltd.
H7N9 bird flu
 
 
ChiCTR-TRC-14005089: Research of clinical treatment system in patients with newly emerging severe acute respiratory infectious diseases

Recruiting
4
356
 
oseltamivir ;peramivir
The First affiliated Hospital, Medical Colleage, Zhejiang University; The first affiliated hospital of guangzhou medical university, Ministry of Science and Technology;
Influenza A
 
 
ChiCTR1900021135: Clinical Effectiveness and safety of Peramivir in the Treatment of Severe Influenza A with Pneumonia

Recruiting
4
40
 
Oral oseltamivir ;Intravenous drip of peramivir
Suqian People's Hospital of Nanjing Gulou Hospital Group; Suqian People's Hospital of Nanjing Gulou Hospital Group, Suqian City's Guiding Science and Technology Project and Suqian People's Hospital of Nanjing Gulou Hospital Group
Severe Influenza A with Pneumonia
 
 
ChiCTR2200056590: The efficacy of peramivir in children with different subtypes of influenza and related influencing factors

Recruiting
4
80
 
Intravenous peramivir; Intravenous peramivir; Intravenous peramivir; Intravenous peramivir
Suqian Hospital of Nanjing Drum Tower Hospital Group; Suqian Hospital of Nanjing Drum Tower Hospital Group, Project of science and technology development foundation of Xuzhou Medical University
Influenza
 
 
ACTRN12607000282482: To evaluate the effects on time to clinical stability associated with treatment with peramivir administered intravenously compared to oral oseltamivir in adults hospitalized with acute serious or potentially life-threatening influenza

Not yet recruiting
2
120
 
BioCryst Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc.
Influenza, Life threatening comorbidities suchs as COPD, congestive heart failure and diabetes.
 
 
ACTRN12607000284460: To evaluate the efficacy of peramivir administered intramuscularly compared to placebo in adult subjects with uncomplicated acute influenza.

Recruiting
2
300
 
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc.
Uncomplicated influenza.
 
 
AD ASTRA, NCT05648448: A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting
2
3000
RoW
Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir
University of Oxford
Influenza, Influenza, Human
01/27
01/27
ChiCTR2300070071: Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic profile of single and multiple doses of peramivir inhalation solution in healthy Chinese adult subjects

Not yet recruiting
1
60
 
Peramivir inhalation solution (initially 20 mg) administered by both oral or face mask nebulized inhalation ;Two cycles of cross-administration of paramivir inhalation solution or paramivir sodium chloride injection ;3:1 randomized, 9 received peramivir inhalation solution and 3 received placebo administration ;3:1 randomized, 9 received peramivir inhalation solution and 3 received placebo administration
Center for Clinical Pharmacology, the Third Xiangya Hospital of Central South University; The third Xiangya Hospital of Central South University, Guangzhou Nanxin Pharmaceutical Co., Ltd.
Influenza
 
 
ChiCTR1800019417: Clinical Effectiveness of Peramivir in the Treatment of Severe Influenza A with Primary Pneumonia

Completed
N/A
45
 
Group A patients were given peramivir sodium chloride injection ;Group B patients received peramivir sodium chloride injection and ribonucleic acid for injection II ;Group C patients were treated with peramivir sodium chloride injection and thymopetidum for injection
Suqian People's Hospital of Nanjing Gulou Hospital Group; Suqian People's Hospital of Nanjing Gulou Hospital Group, Personal research fund
Severe Influenza A with Primary Pneumonia
 
 
Orladeyo (berotralstat) / BioCryst
APeX-P, NCT05453968 / 2021-005932-50: Berotralstat Treatment in Children With Hereditary Angioedema

Active, not recruiting
3
29
Europe, Canada, RoW
Berotralstat, BCX7353, Orladeyo®
BioCryst Pharmaceuticals
Hereditary Angioedema, Pediatric
09/24
02/27
APeX-A, NCT04933721 / 2020-004230-37: Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

Active, not recruiting
3
110
Europe, RoW
berotralstat, Orladeyo
BioCryst Pharmaceuticals
Hereditary Angioedema, HAE
08/26
08/26
2015-003923-74: A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAE

Ongoing
2
24
Europe
BC7353, BCX7353, Capsule, hard
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceutical Inc
Hereditary Angioedema, Hereditary Angioedema, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
pelecopan (BCX9930) / BioCryst
2020-005855-19: Evaluating oral BCX9930 in renal diseases

Not yet recruiting
2
42
Europe
BCX9930, BCX9930, Tablet
BioCryst Pharmaceuticals Inc, BIOCRYST PHARMACEUTICALS INC., BioCryst Pharmaceuticals Inc
complement 3 glomerulopathyimmunoglobulin A nephropathyprimary membranous nephropathy glomerulopatía del complemento 3 (C3G)nefropatía por inmunoglobulina A (IgAN)nefropatía membranosa primaria (PMN), C3 GIgA nephropathyprimary membranous nephropathy glomerulopatía del complemento 3 (C3G)nefropatía por inmunoglobulina A (IgAN)nefropatía membranosa primaria (PMN), Body processes [G] - Immune system processes [G12]
 
 
2021-006776-17: REDEEM - access to BCX9930

Ongoing
2
200
Europe
BCX9930, BCX9930, Tablet
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc
Paroxysmal Nocturnal Hemoglobinuria, PNH, Diseases [C] - Immune System Diseases [C20]
 
 
REDEEM-2, NCT05116787 / 2020-004403-14: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy

Terminated
2
12
RoW
Placebo, BCX9930 monotherapy
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/23
09/23
REDEEM-1, NCT05116774 / 2020-004438-39: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

Terminated
2
12
Europe
Eculizumab, Soliris, Ravulizumab, Ultomiris, ALXN1210, ravulizumab-cwvz, BCX9930
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/23
09/23
NCT04702568 / 2020-000501-93: A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Terminated
2
19
Europe, RoW
BCX9930, Eculizumab, Ravulizumab
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria, PNH
10/23
10/23
NCT05741346 / 2021-006776-17: Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

Active, not recruiting
2
28
Europe, RoW
BCX9930
BioCryst Pharmaceuticals, BioCryst Pharmaceuticals Inc
Paroxysmal Nocturnal Hemoglobinuria
02/26
02/26
BCX9250 / BioCryst
No trials found
BCX9499 / BioCryst
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rapivab (peramivir) / BioCryst
ChiCTR-IPR-15006047: REDUNING, a kind of traditional Chinese medicine injections, in the treatment of human H7N9 bird flu: A single-center, randomized, open, controlled clinical trial

Recruiting
4
60
 
Peramivir injection+REDUNING injection ;Peramivir injection
First Affiliated Hospital, College of Medcine, Zhejiang University; First Affiliated Hospital, College of Medcine, Zhejiang University, Jiangsu Kanion Pharmaceutical Co., Ltd.
H7N9 bird flu
 
 
ChiCTR-TRC-14005089: Research of clinical treatment system in patients with newly emerging severe acute respiratory infectious diseases

Recruiting
4
356
 
oseltamivir ;peramivir
The First affiliated Hospital, Medical Colleage, Zhejiang University; The first affiliated hospital of guangzhou medical university, Ministry of Science and Technology;
Influenza A
 
 
ChiCTR1900021135: Clinical Effectiveness and safety of Peramivir in the Treatment of Severe Influenza A with Pneumonia

Recruiting
4
40
 
Oral oseltamivir ;Intravenous drip of peramivir
Suqian People's Hospital of Nanjing Gulou Hospital Group; Suqian People's Hospital of Nanjing Gulou Hospital Group, Suqian City's Guiding Science and Technology Project and Suqian People's Hospital of Nanjing Gulou Hospital Group
Severe Influenza A with Pneumonia
 
 
ChiCTR2200056590: The efficacy of peramivir in children with different subtypes of influenza and related influencing factors

Recruiting
4
80
 
Intravenous peramivir; Intravenous peramivir; Intravenous peramivir; Intravenous peramivir
Suqian Hospital of Nanjing Drum Tower Hospital Group; Suqian Hospital of Nanjing Drum Tower Hospital Group, Project of science and technology development foundation of Xuzhou Medical University
Influenza
 
 
ACTRN12607000282482: To evaluate the effects on time to clinical stability associated with treatment with peramivir administered intravenously compared to oral oseltamivir in adults hospitalized with acute serious or potentially life-threatening influenza

Not yet recruiting
2
120
 
BioCryst Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc.
Influenza, Life threatening comorbidities suchs as COPD, congestive heart failure and diabetes.
 
 
ACTRN12607000284460: To evaluate the efficacy of peramivir administered intramuscularly compared to placebo in adult subjects with uncomplicated acute influenza.

Recruiting
2
300
 
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc.
Uncomplicated influenza.
 
 
AD ASTRA, NCT05648448: A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting
2
3000
RoW
Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir
University of Oxford
Influenza, Influenza, Human
01/27
01/27
ChiCTR2300070071: Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic profile of single and multiple doses of peramivir inhalation solution in healthy Chinese adult subjects

Not yet recruiting
1
60
 
Peramivir inhalation solution (initially 20 mg) administered by both oral or face mask nebulized inhalation ;Two cycles of cross-administration of paramivir inhalation solution or paramivir sodium chloride injection ;3:1 randomized, 9 received peramivir inhalation solution and 3 received placebo administration ;3:1 randomized, 9 received peramivir inhalation solution and 3 received placebo administration
Center for Clinical Pharmacology, the Third Xiangya Hospital of Central South University; The third Xiangya Hospital of Central South University, Guangzhou Nanxin Pharmaceutical Co., Ltd.
Influenza
 
 
ChiCTR1800019417: Clinical Effectiveness of Peramivir in the Treatment of Severe Influenza A with Primary Pneumonia

Completed
N/A
45
 
Group A patients were given peramivir sodium chloride injection ;Group B patients received peramivir sodium chloride injection and ribonucleic acid for injection II ;Group C patients were treated with peramivir sodium chloride injection and thymopetidum for injection
Suqian People's Hospital of Nanjing Gulou Hospital Group; Suqian People's Hospital of Nanjing Gulou Hospital Group, Personal research fund
Severe Influenza A with Primary Pneumonia
 
 
Orladeyo (berotralstat) / BioCryst
APeX-P, NCT05453968 / 2021-005932-50: Berotralstat Treatment in Children With Hereditary Angioedema

Active, not recruiting
3
29
Europe, Canada, RoW
Berotralstat, BCX7353, Orladeyo®
BioCryst Pharmaceuticals
Hereditary Angioedema, Pediatric
09/24
02/27
APeX-A, NCT04933721 / 2020-004230-37: Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

Active, not recruiting
3
110
Europe, RoW
berotralstat, Orladeyo
BioCryst Pharmaceuticals
Hereditary Angioedema, HAE
08/26
08/26
2015-003923-74: A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAE

Ongoing
2
24
Europe
BC7353, BCX7353, Capsule, hard
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceutical Inc
Hereditary Angioedema, Hereditary Angioedema, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
pelecopan (BCX9930) / BioCryst
2020-005855-19: Evaluating oral BCX9930 in renal diseases

Not yet recruiting
2
42
Europe
BCX9930, BCX9930, Tablet
BioCryst Pharmaceuticals Inc, BIOCRYST PHARMACEUTICALS INC., BioCryst Pharmaceuticals Inc
complement 3 glomerulopathyimmunoglobulin A nephropathyprimary membranous nephropathy glomerulopatía del complemento 3 (C3G)nefropatía por inmunoglobulina A (IgAN)nefropatía membranosa primaria (PMN), C3 GIgA nephropathyprimary membranous nephropathy glomerulopatía del complemento 3 (C3G)nefropatía por inmunoglobulina A (IgAN)nefropatía membranosa primaria (PMN), Body processes [G] - Immune system processes [G12]
 
 
2021-006776-17: REDEEM - access to BCX9930

Ongoing
2
200
Europe
BCX9930, BCX9930, Tablet
BioCryst Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc
Paroxysmal Nocturnal Hemoglobinuria, PNH, Diseases [C] - Immune System Diseases [C20]
 
 
REDEEM-2, NCT05116787 / 2020-004403-14: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy

Terminated
2
12
RoW
Placebo, BCX9930 monotherapy
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/23
09/23
REDEEM-1, NCT05116774 / 2020-004438-39: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

Terminated
2
12
Europe
Eculizumab, Soliris, Ravulizumab, Ultomiris, ALXN1210, ravulizumab-cwvz, BCX9930
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/23
09/23
NCT04702568 / 2020-000501-93: A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Terminated
2
19
Europe, RoW
BCX9930, Eculizumab, Ravulizumab
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria, PNH
10/23
10/23
NCT05741346 / 2021-006776-17: Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

Active, not recruiting
2
28
Europe, RoW
BCX9930
BioCryst Pharmaceuticals, BioCryst Pharmaceuticals Inc
Paroxysmal Nocturnal Hemoglobinuria
02/26
02/26
BCX9250 / BioCryst
No trials found
BCX9499 / BioCryst
No trials found

Download Options